Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia

Leukemia

Volumn 14, Issue 1, 2000, Pages 61-67

  Zhou, M ^a   Gu, L ^a   Abshire, T C ^a   Homans, A ^b   Billett, A L ^c   Yeager, A M ^a   Findley, H W ^a   Findley, H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

MDM2 oncoprotein; Relapsed acute lymphoblastic leukemia

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; PROTEIN MDM2; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B CELL LEUKEMIA; BONE MARROW CELL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SCHOOL CHILD; SINGLE STRAND CONFORMATION POLYMORPHISM; WESTERN BLOTTING;

EID: 0033959324     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401619     Document Type: Article

References (21)

1. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
2. Chen J, Wu X, Lin J, Levine AJ, mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996; 16: 2445-2452.
3. Wu X, Bayle J, Olson D, Levine A. The p53-MDM2 autoregulatory feedback loop. Genes Dev 1993; 7: 1125-1132.
4. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 1996; 15: 1596-1606.
5. Piette J, Neel H, Marechal V. MDM2: keeping p53 under control. Oncogene 1997; 15: 1001-1010.
6. Sigalas J, Calvert AH, Andersen JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med 1996; 2: 912-917.
7. Lundgren K, Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozana G, Rosenberg MP, Finlay CA. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997; 11: 714-725.
8. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradly A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998; 95: 15608-15612.
9. Quesnel B, Preudhomme C, Oscier D, Lepelley P, O'Hooghe MC, Facon T, Zandecki M, Fenaux P. Overexpression of the mdm-2 gene is found in some cases of haematological malignancies. Br J Haematol 1994; 88: 415-418.
10. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The humanMDM2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-2623.
11. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995; 85: 1608-1614.
12. Marks DJ, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Brodsky I, Haines DS. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155-1161.
13. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky I, Haines DS. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997; 15: 1158-1162.
14. Gustafsson B, Stal O, Gustafsson B. Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Ped Hematol Oncol 1998; 15: 519-526.
15. Poplack DG. Acute lymphoblastic leukemia. In: Pizzo P, Poplack DG (eds). Principles and Practice of Pediatric Oncology. JB Lippincott: Philadelphia, PA, 1997, pp 433.
16. Roehm N, Rodgers G, Hatfield S, Glasebrook A. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Meth 1991; 142: 257-265.
17. Rothenberg ML, Mickley L, Cole DE. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 1989; 74: 1388-1395.
18. Stammler G, Sauerbrey A, Volm M. Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytotochemistry and RT-PCR. Cancer Lett 1994; 84: 141-147.
19. Klumper E, Giaccone G, Pieters R, Broekema G, van Arke-Otte J, van Wering ER, Kaspers GJ, Veerman AJ. Topoisomerase Na gene expression in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1653-1660.
20. Wada M, Bartram CR, Nakamura H, Hackiya M, Chen D-L, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP. Analysis of p53 mutations in a large series of lymphoid malignancies of childhood. Blood 1993; 82: 3163-3169.
21. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao L-E, Yu AL. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994; 84: 3105-3112.